RA Capital Management Reports 4.8% Stake in Dianthus Therapeutics, Inc. (DNTH)

RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and the RA Capital Healthcare Fund, L.P., filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Dianthus Therapeutics, Inc. (DNTH). As of the event date on March 31, 2026, the reporting persons collectively reported beneficial ownership of 2,611,733 shares of common stock. This position represents approximately 4.8% of the company's outstanding shares, based on 54,448,771 shares reported as of March 30, 2026. This filing marks an increase from a previously reported zero percent ownership, indicating a new significant position for the group. RA Capital Healthcare Fund directly holds the shares, while RA Capital Management serves as the investment adviser with delegated voting and dispositive power. The reporting persons have certified that these shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.